MPG.eBooks - Description: Olopatadine for the treatment of allergic conjunctivitis

Cover Image

Read Now

Olopatadine for the treatment of allergic conjunctivitis a review of the clinical efficacy, safety, and cost-effectiveness

This Rapid Response report aims to review the clinical- and cost-effectiveness of olopatadine for the treatment of allergic conjunctivitis. This is an update to the previous CADTH Rapid Response review from 2012

Bibliographic Details
Corporate Authors:	Canadian Agency for Drugs and Technologies in Health, Canadian Agency for Drugs and Technologies in Health Rapid Response Service
Format:	eBook
Language:	English
Published:	Ottawa (ON) Canadian Agency for Drugs and Technologies in Health 2016, 17 March 2016
Series:	Rapid response report : summary with critical appraisal
Subjects:	Anti-allergic Agents / Therapeutic Use Anti-inflammatory Agents, Non-steroidal / Therapeutic Use Canada Olopatadine Hydrochloride / Therapeutic Use Conjunctivitis, Allergic / Drug Therapy Cost-benefit Analysis Treatment Outcome Histamine H1 Antagonists, Non-sedating / Therapeutic Use
Online Access:	https://www.ncbi.nlm.nih.gov/books/NBK355639
Collection:	National Center for Biotechnology Information - Collection details see MPG.ReNa

Description
Summary:	This Rapid Response report aims to review the clinical- and cost-effectiveness of olopatadine for the treatment of allergic conjunctivitis. This is an update to the previous CADTH Rapid Response review from 2012
Item Description:	"CADTH Rapid Response Service."
Physical Description:	1 PDF file (13 pages) illustration